Pentadeca Arginate
unknown riskAlso: PDA · Pentadecapeptide Arginate · BPC-157 Arginine Variant
Pentadeca Arginate (PDA) is an arginine-modified analog of BPC-157, engineered to enhance stability and potentially improve tissue-regenerative properties. Developed as a compounding-friendly alternative following FDA restrictions on BPC-157, PDA shares a similar 15-amino-acid backbone with the addition of an arginine salt modification. Preclinical evidence is emerging, and human data is absent.
Reported Benefits
Gut and mucosal healing
Early animal data suggest tissue-protective effects similar to BPC-157 in GI injury models, though direct comparative trials are lacking.
Tendon and connective tissue repair
Mechanistic overlap with BPC-157 suggests collagen synthesis promotion, but independent studies are sparse.
Anti-inflammatory effects
Rodent models show attenuation of inflammatory markers in colitis and wound models; not yet validated in humans.
Mechanism of Action
Presumed to share BPC-157's core mechanism — upregulation of GH receptor expression, VEGF-driven angiogenesis, FAK-paxillin pathway activation for connective tissue repair, and nitric oxide modulation. The arginine modification may improve mucosal permeability and bioavailability.
Key Clinical Studies
Preclinical (various) (2023)
Exploratory · Animal (rat)
Tissue-protective effects observed in GI and wound models; PDA-specific RCTs not yet published
Overview
Pentadeca Arginate (PDA) emerged primarily as a regulatory workaround after the FDA placed BPC-157 on its list of bulk substances that may not be used in compounding. PDA retains the 15-amino-acid core of BPC-157 with an arginine salt modification designed to maintain biological activity while technically differing from the restricted compound. Whether this modification meaningfully alters pharmacokinetics or efficacy is not yet established in peer-reviewed literature.
Evidence Summary
The evidence base for PDA as a distinct compound is thin. Most practitioners and researchers extrapolate from the robust BPC-157 preclinical literature (100+ animal studies) while assuming similar mechanisms. PDA-specific research is limited to a handful of unpublished or early-stage studies. Until independent trials are conducted, PDA’s efficacy claims rest largely on structural similarity to BPC-157, not its own data.
Regulatory Status
PDA occupies a gray area. It was not specifically named in the FDA’s BPC-157 restrictions, making it temporarily available through some US compounding pharmacies. However, the FDA’s rationale for restricting BPC-157 — lack of adequate safety data and marketing as a drug ingredient — could extend to structural analogs. Regulatory status may shift. This compound is for research purposes only.
Most Common Use Cases
PDA is used in clinical settings primarily by practitioners who previously prescribed BPC-157 for gut permeability issues, IBD, SIBO, tendon injuries, and post-surgical tissue repair. Oral and injectable routes are both used. It is not approved for human use, and all administration is off-label.
✦ Sponsored
Stop Guessing About Your Health. Start Optimizing It.
Advanced diagnostics and licensed medical providers delivering personalized longevity care to uncover root causes, optimize health, and track progress virtually or in person.
Learn More →
Regulatory Status
Research OnlySafety Profile
Side Effects
- •Injection site irritation
- •Nausea (oral route)
- •Transient fatigue (reported anecdotally)
Contraindications
- •Active malignancy (theoretical)
- •Pregnancy
- •Known arginine hypersensitivity
Drug Interactions
- •NSAIDs (may reduce healing efficacy)
- •Immunosuppressants (unknown interaction)
Primary Uses
Planning a protocol?
Use the AI Stack Builder to generate a phased schedule, compatibility analysis, and monitoring checklist.
Weekly Briefing
Regulatory updates + new study breakdowns.
For Practitioners
Do you prescribe Pentadeca Arginate?
Get in front of patients who've already researched this protocol and are ready to consult. Featured listings from $199/mo.
Get Listed →